Jul 25, 2024, 23:48
ESTRO – To Escalate or to De-Escalate Radiation Dose in Stage 3 NSCLC?
European Society for Radiotherapy and Oncology shared on LinkedIn:
“Key insights from ESTRO24 on the optimisation of radiation doses for stage III NSCLC in the era of immunotherapy and tyrosine kinase inhibitors. Learn about dose escalation trials, individualised treatment strategies, and the role of biomarkers in the guidance of therapy.”
Read further.
Source: European Society for Radiotherapy and Oncology/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 10:18
Nov 20, 2024, 06:51
Nov 20, 2024, 01:07
Nov 20, 2024, 01:00
Nov 20, 2024, 00:40